So far, the pharmacological treatment for AD and other neurodegenerative dementias has been mostly based on symptomatic drugs enhancing cognition and reducing behavioral alterations (antipsychotic drugs, acetylcholinesterase inhibitors, and NMDA receptor antagonist) with contrasting results and no efficacy in modifying disease progression [122]. This evidence concerns the gene ACHE and Alzheimer disease.